Issue 11, 2005

Synthesis and biological evaluation of novel fumagillin and ovalicin analogues

Abstract

A promising approach among the numerous efforts to cure cancer is the interruption of the tumour-induced formation of new blood vessels (angiogenesis). By suppressing angiogenesis with drugs, the tumour can neither grow to a life threatening size, nor metastasize. The natural product fumagillin 1 and the structurally related ovalicin 2 are two of the most potent anti-angiogenic compounds. Here, we report the design and synthesis of novel fumagillin and ovalicin analogues lacking reactive epoxy functionalities, which were thought to be responsible for the severe toxic side-effects observed. We also report a new synthetic approach and the determination of the anti-angiogenic properties of these compounds in endothelial cells.

Graphical abstract: Synthesis and biological evaluation of novel fumagillin and ovalicin analogues

Supplementary files

Article information

Article type
Paper
Submitted
03 Mar 2005
Accepted
13 Apr 2005
First published
22 Apr 2005

Org. Biomol. Chem., 2005,3, 2150-2154

Synthesis and biological evaluation of novel fumagillin and ovalicin analogues

R. Mazitschek, A. Huwe and A. Giannis, Org. Biomol. Chem., 2005, 3, 2150 DOI: 10.1039/B503163J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements